Open Payments

ANDERSON CLINICAL RESEARCH

Type
Non-covered entity
Where
REDLANDS, CA
Received
$1,534,209 in 322 records, 2019 to 2025 ($0 general, $1,534,209 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment34$501,456
2024Research payment2$3,821
2023Research payment5$16,658
2022Research payment8$20,303
2021Research payment35$60,800
2020Research payment56$111,781
2019Research payment182$819,388

By company

CompanyRecordsAmountYears
Axsome Therapeutics, Inc.23$433,0162025
Alkermes, Inc.171$347,3772019–2023
Biogen, Inc.2$258,7242019–2020
Otsuka Pharmaceutical Development & Commercialization, Inc.4$110,9992019
Allergan, Inc.14$81,6042019–2021
Genentech, Inc.10$75,3492019
Eli Lilly and Company32$67,4432019–2025
Eisai Inc.26$48,9142019
Boehringer Ingelheim Pharmaceuticals, Inc.3$41,4542019–2021
E.R. Squibb & Sons, L.L.C.2$40,3772025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)7$26,5232025
Teva Pharmaceuticals USA, Inc.1$1,5002019
Boehringer Ingelheim RCV GmbH & Co KG27$9262019–2020

By nature of payment

NatureRecordsAmount
Research payment322$1,534,209

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-11Axsome Therapeutics, Inc.$21,987Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-12-11Axsome Therapeutics, Inc.$35Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-11-14Axsome Therapeutics, Inc.$30,234Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-11-14Axsome Therapeutics, Inc.$105Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-11-10ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$1,900Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-10-17Axsome Therapeutics, Inc.$36,948Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-10-17Axsome Therapeutics, Inc.$315Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-10-13ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$4,298Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-10-06E.R. Squibb & Sons, L.L.C.$38,940Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar2025
2025-10-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$1,478Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-10-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$114Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-09-15Axsome Therapeutics, Inc.$48,395Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-09-15Axsome Therapeutics, Inc.$4,835Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-09-08ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$11,290Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-09-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$60Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-08-26E.R. Squibb & Sons, L.L.C.$1,437Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar2025
2025-08-13Axsome Therapeutics, Inc.$40,447Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-08-13Axsome Therapeutics, Inc.$140Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-08-04ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)$7,382Research paymentCash or cash equivalentA Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-07-23Axsome Therapeutics, Inc.$53,023Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-07-23Axsome Therapeutics, Inc.$240Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-06-13Axsome Therapeutics, Inc.$57,188Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-06-13Axsome Therapeutics, Inc.$2,070Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-05-16Axsome Therapeutics, Inc.$43,469Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-05-16Axsome Therapeutics, Inc.$105Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-04-16Axsome Therapeutics, Inc.$45,164Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-04-16Axsome Therapeutics, Inc.$1,106Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-03-24Axsome Therapeutics, Inc.$14,921Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-02-25Eli Lilly and Company$607Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-02-18Axsome Therapeutics, Inc.$22,814Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-02-14Axsome Therapeutics, Inc.$182Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-02-12Eli Lilly and Company$931Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2025
2025-01-14Axsome Therapeutics, Inc.$8,688Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-01-14Axsome Therapeutics, Inc.$600Research paymentCash or cash equivalentA Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2024-01-31Eli Lilly and Company$1,924Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2024-01-17Eli Lilly and Company$1,896Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2024
2023-11-24Alkermes, Inc.$5,989Research paymentCash or cash equivalentLYBALVI Drug, CNSStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312023
2023-05-10Eli Lilly and Company$663Research paymentIn-kind items and servicesASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2023
2023-01-26Eli Lilly and Company$5,002Research paymentIn-kind items and servicesASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER2023
2023-01-26Eli Lilly and Company$3,134Research paymentIn-kind items and servicesA STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2)2023
2023-01-13Eli Lilly and Company$1,867Research paymentIn-kind items and servicesA PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM2023
2022-07-06Eli Lilly and Company$6,046Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2022
2022-06-24Alkermes, Inc.$649Research paymentCash or cash equivalentLYBALVI Drug, CNSA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2022
2022-03-25Alkermes, Inc.$1,848Research paymentCash or cash equivalentLYBALVI Drug, CNSA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2022
2022-03-08Eli Lilly and Company$31Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2022
2022-01-28Alkermes, Inc.$1,351Research paymentCash or cash equivalentLYBALVI Drug, CNSA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2022
2022-01-20Eli Lilly and Company$7,031Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022
2022-01-11Eli Lilly and Company$2,389Research paymentIn-kind items and servicesA PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES2022
2022-01-05Eli Lilly and Company$957Research paymentIn-kind items and servicesA PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS 2022
2021-12-31Allergan, Inc.$689Research paymentIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCEA DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-12-31Allergan, Inc.$525Research paymentIn-kind items and servicesVRAYLAR Drug, NEUROSCIENCEA DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2021
2021-12-31Allergan, Inc.$200Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATO2021
2021-12-23Alkermes, Inc.$3,034Research paymentCash or cash equivalentOLANZAPINE Drug, CNSA Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc2021
2021-11-26Alkermes, Inc.$1,404Research paymentCash or cash equivalentOLANZAPINE Drug, CNSA Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc2021
2021-11-24Eli Lilly and Company$195Research paymentIn-kind items and servicesA PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS 2021
2021-10-29Alkermes, Inc.$2,538Research paymentCash or cash equivalentOLANZAPINE Drug, CNSA Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc2021
2021-10-25Alkermes, Inc.$22,239Research paymentIn-kind items and servicesLYBALVI Drug, CNSA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-10-01Alkermes, Inc.$3,034Research paymentCash or cash equivalentA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-09-30Alkermes, Inc.$192Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-08-27Alkermes, Inc.$3,511Research paymentCash or cash equivalentA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-08-23Eli Lilly and Company$6Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2021
2021-08-17Alkermes, Inc.$192Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-08-17Alkermes, Inc.$192Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-08-05Boehringer Ingelheim Pharmaceuticals, Inc.$906Research paymentCash or cash equivalentPoCC dose finding in Mild to Moderate AD2021
2021-05-10Eli Lilly and Company$65Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2021
2021-05-10Eli Lilly and Company$7Research paymentIn-kind items and servicesA RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS2021
2021-05-03Eli Lilly and Company$4,916Research paymentIn-kind items and servicesA PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES2021
2021-04-27Eli Lilly and Company$75Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLA2021
2021-04-26Eli Lilly and Company$75Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2021
2021-04-08Eli Lilly and Company$65Research paymentIn-kind items and servicesA STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A2021
2021-04-08Eli Lilly and Company$61Research paymentIn-kind items and servicesA PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2021
2021-04-08Eli Lilly and Company$15Research paymentIn-kind items and servicesA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUAT2021
2021-04-08Eli Lilly and Company$4Research paymentIn-kind items and servicesA RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS2021
2021-03-26Alkermes, Inc.$1,404Research paymentCash or cash equivalentA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-02-26Alkermes, Inc.$3,293Research paymentCash or cash equivalentA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-29Eli Lilly and Company$7,505Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2021
2021-01-29Alkermes, Inc.$3,075Research paymentCash or cash equivalentA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-29Eli Lilly and Company$703Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2021
2021-01-13Alkermes, Inc.$194Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-13Alkermes, Inc.$192Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-13Alkermes, Inc.$138Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-13Alkermes, Inc.$115Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-13Alkermes, Inc.$18Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2021-01-13Alkermes, Inc.$10Research paymentIn-kind items and servicesA Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject2021
2020-11-19Eli Lilly and Company$1,499Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2020
2020-09-01Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-08-01Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-07-30Alkermes, Inc.$3,321Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-07-17Eli Lilly and Company$360Research paymentCash or cash equivalentAN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR2020
2020-06-25Alkermes, Inc.$20,251Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-06-01Alkermes, Inc.$3,559Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-06-01Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-05-14Alkermes, Inc.$1,270Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-05-08Alkermes, Inc.$3,252Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-05-01Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-04-16Alkermes, Inc.$1,694Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-04-14Alkermes, Inc.$194Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-14Alkermes, Inc.$192Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-14Alkermes, Inc.$192Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-14Alkermes, Inc.$138Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-14Alkermes, Inc.$18Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-13Alkermes, Inc.$194Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-13Alkermes, Inc.$192Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-13Alkermes, Inc.$192Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-13Alkermes, Inc.$18Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-13Alkermes, Inc.$13Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-02Alkermes, Inc.$5,182Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-04-01Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-04-01Alkermes, Inc.$13Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-04-01Alkermes, Inc.$13Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-03-19Alkermes, Inc.$154Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-03-19Alkermes, Inc.$22Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-03-12Alkermes, Inc.$3,901Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-03-02Alkermes, Inc.$3,777Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-27Alkermes, Inc.$2,962Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-02-20Alkermes, Inc.$847Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-02-10Alkermes, Inc.$192Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$115Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$97Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$69Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$42Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$9Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-10Alkermes, Inc.$5Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-03Alkermes, Inc.$3,293Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-02-01Alkermes, Inc.$50Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-01-31Eli Lilly and Company$857Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2020
2020-01-30Boehringer Ingelheim Pharmaceuticals, Inc.$9,666Research paymentCash or cash equivalentPoCC dose finding in Mild to Moderate AD2020
2020-01-24Alkermes, Inc.$375Research paymentCash or cash equivalentA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2020
2020-01-23Alkermes, Inc.$7,230Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-01-23Alkermes, Inc.$2,962Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-01-10Alkermes, Inc.$11,145Research paymentCash or cash equivalentA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2020
2020-01-10Alkermes, Inc.$3,293Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312020
2020-01-09Alkermes, Inc.$12,764Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-01-09Alkermes, Inc.$1,694Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-01-09Alkermes, Inc.$1,691Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2020
2020-01-02Biogen, Inc.$2,192Research paymentCash or cash equivalent221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease2020
2020-01-01Alkermes, Inc.$90Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-01-01Alkermes, Inc.$90Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2020
2020-01-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2020
2020-01-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2020
2019-12-31Allergan, Inc.$12,751Research paymentCash or cash equivalentVRAYLAR Drug, NEUROSCIENCEA DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER2019
2019-12-31Allergan, Inc.$681Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION 2019
2019-12-31Allergan, Inc.$110Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION 2019
2019-12-12Alkermes, Inc.$9,886Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-12-04Alkermes, Inc.$3,911Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-12-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-12-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-11-25Genentech, Inc.$5,772Research paymentCash or cash equivalentNon-Covered Product Drug, NonePRODROMAL TO MILD AD2019
2019-11-18Alkermes, Inc.$124Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-11-18Alkermes, Inc.$21Research paymentIn-kind items and servicesStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-11-07Alkermes, Inc.$12,214Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-11-06Alkermes, Inc.$2,797Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-11-05Alkermes, Inc.$1,936Research paymentCash or cash equivalentA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-11-01Alkermes, Inc.$120Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-11-01Alkermes, Inc.$50Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-11-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-11-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-11-01Alkermes, Inc.$12Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-10-31Alkermes, Inc.$85Research paymentIn-kind items and servicesA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-10-24Genentech, Inc.$1,000Research paymentCash or cash equivalentNon-Covered Product Drug, NonePRODROMAL TO MILD AD2019
2019-10-17Alkermes, Inc.$735Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-10-09Genentech, Inc.$17,032Research paymentCash or cash equivalentNon-Covered Product Drug, NonePRODROMAL TO MILD AD2019
2019-10-02Genentech, Inc.$400Research paymentCash or cash equivalentNon-Covered Product Drug, NonePRODROMAL TO MILD AD2019
2019-10-01Alkermes, Inc.$90Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-10-01Alkermes, Inc.$90Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-10-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-10-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-09-30Alkermes, Inc.$1,094Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-09-30Alkermes, Inc.$487Research paymentCash or cash equivalentA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-09-30Alkermes, Inc.$85Research paymentIn-kind items and servicesA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-09-25Alkermes, Inc.$6,323Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-09-25Alkermes, Inc.$1,694Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2019
2019-09-03Alkermes, Inc.$2,036Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-09-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-09-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-08-31Alkermes, Inc.$85Research paymentIn-kind items and servicesA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-08-27Alkermes, Inc.$1,700Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-08-27Alkermes, Inc.$847Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2019
2019-08-23Alkermes, Inc.$675Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-08-22Eisai Inc.$16,276Research paymentCash or cash equivalent DrugA Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lembor2019
2019-08-22Eisai Inc.$941Research paymentCash or cash equivalent DrugA Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lembor2019
2019-08-08Alkermes, Inc.$2,802Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-08-08Alkermes, Inc.$847Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2019
2019-08-08Alkermes, Inc.$625Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-08-06Allergan, Inc.$7,814Research paymentCash or cash equivalentAN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER 2019
2019-08-03Alkermes, Inc.$2,036Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019
2019-08-03Alkermes, Inc.$1,647Research paymentCash or cash equivalentA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-08-01Alkermes, Inc.$50Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-08-01Alkermes, Inc.$40Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-08-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-08-01Boehringer Ingelheim RCV GmbH & Co KG$34Research paymentIn-kind items and servicesPoCC/dose-finding in Mild to Moderate AD2019
2019-08-01Alkermes, Inc.$12Research paymentIn-kind items and servicesA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-07-31Alkermes, Inc.$85Research paymentIn-kind items and servicesA Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia2019
2019-07-18Alkermes, Inc.$8,549Research paymentCash or cash equivalentOLANZAPINE Drug, CNSA Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia2019
2019-07-11Alkermes, Inc.$1,700Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-07-11Alkermes, Inc.$1,268Research paymentCash or cash equivalentA Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder2019
2019-07-11Alkermes, Inc.$579Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-07-11Alkermes, Inc.$320Research paymentCash or cash equivalentA Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder2019
2019-07-08Genentech, Inc.$3,809Research paymentCash or cash equivalentNon-Covered Product Drug, NonePRODROMAL TO MILD AD2019
2019-07-02Alkermes, Inc.$3,508Research paymentCash or cash equivalentStudy to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 38312019

The latest 200 records of 322.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Bernardino CountyRedlands city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Redlands, CA, county San Bernardino County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Redlands, CA
County
San Bernardino County, CA
State
California
Population B0100373,3752,197,10439,287,377
Population, 2020 census P173,1682,181,65439,538,223
Median age B0100234.634.737.9
Under 18 B0100123.9%25.5%22.0%
65 and over B0100114.9%12.6%15.7%
Households B1100125,152674,91513,548,091
Foreign born B0500216.8%21.6%27.0%
Median household income B19013$105,041$85,478$99,122
Median family income B19113$116,512$93,416$113,346
Per capita income B19301$49,007$34,343$49,513
Poverty rate B170019.1%13.3%12.0%
Unemployment rate B230255.5%7.1%6.6%
Civilian labor force B2302537,1121,046,62420,068,466
Mean commute (minutes) B0801324.932.628.7
Bachelor's degree or higher B1500341.5%23.3%37.1%
Housing units B2500126,256743,88614,644,735
Owner-occupied B2500356.8%62.1%55.9%
Renters B2500343.2%37.9%44.1%
Median home value B25077$618,900$505,000$734,700
Median gross rent B25064$2,005$1,801$2,036
White, not Hispanic B0300240.6%24.7%33.8%
Black B030025.6%7.5%5.2%
Hispanic or Latino B0300239.5%55.2%40.2%
Asian B030028.2%8.1%15.3%
American Indian and Alaska Native B030020.2%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Redlands, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.